Endometrial Cancer Clinical Trials in Denver, Colorado

11 studies are recruiting for endometrial cancer in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Rocky Mountain Cancer Center, Denver, Colorado

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

   This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   AdventHealth Porter, Denver, Colorado

   Locations

   121 in total

   Run by

   Canadian Cancer Trials Group

   See if you can join NCT05640999 on ClinicalTrials.gov

3. A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

   This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive soli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI at Denver Health, Denver, Colorado

   Locations

   15 in total

   Run by

   Context Therapeutics Inc.

   See if you can join NCT06515613 on ClinicalTrials.gov

4. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

   This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Denver, Denver, Colorado

   Locations

   9 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07227168 on ClinicalTrials.gov

5. A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

   This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) at HealthONE-Denver, Denver, Colorado

   Locations

   11 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT07383506 on ClinicalTrials.gov

6. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Denver, Colorado

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

7. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver, Colorado

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

8. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Rocky Mountain Cancer Center, Denver, Colorado

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

9. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Denver, Colorado

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

10. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, Denver, Colorado

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov

11. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Denver, Colorado

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov